



Photo: Adobe Stock

NEUREX / MEDALIS
WORKSHOP

DECEMBER
7TH, 2020
ILLKIRCH

VENUE
7HOTEL
550 BLD SÉBASTIEN BRANT
67400 ILLKIRCH

ORGANIZERS
DR DIDIER ROGNAN
DR JEAN-CHRISTOPHE PETER
DR FRÉDÉRIC SIMONIN



 Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

— PROJECT INTERNEURON —

Program Interreg V Upper Rhine «Transcending borders with every project», Neurex, Médalis, BioValley France, CNRS, Université de Strasbourg, Région Grand Est, Département du Bas-Rhin, Département du Haut-Rhin, Eurométropole Strasbourg, Hôpitaux Universitaires de Strasbourg, Bernstein Center Freiburg, Klinik für Psychiatrie und Psychotherapie Freiburg, Neurozentrum Freiburg, Universität Freiburg, Universität Basel, Universitäre Psychiatrische Kliniken Basel, Kanton Aargau, Kanton Basel-Landschaft, Confédération suisse.

THERAPEUTIC CHALLENGES IN THE TREATMENT OF PAIN

MONDAY, DECEMBER 7TH, 2020

09.00 — 09.30 WELCOME COFFEE

09.30 — 10.30

Ipek Yalcin —

CNRS UPR 3212, Institut des Neurosciences Cellulaires et Intégratives, Strasbourg, France

"Can opto-omics approaches accelerate the discovery of new targets for pain relief: Insight from preclinical studies?"

10.30 — 11.30

Didier Bouhassira —

INSERM U987, Hôpital Ambroise Paré, Boulogne-Billancourt, France

"Multiple challenges of translational neuropathic pain research"

11.30 — 12.30

Pierre Sokoloff —

CSO Biodel Therapeutics, Clapiers, France

"Allosteric negative inhibitors of the FLT3 tyrosine kinase receptor: a new therapeutic approach for the treatment of chronic pain"

12.30 — 14.00 LUNCH BREAK

14.00 — 15.00

Mirela Muresan —

Centre d'évaluation et de traitement de la douleur, Strasbourg, France

"Central sensitisation as a diagnostic and therapeutic challenge in chronic headache syndromes"

15.00 — 16.00

Eric Lingueglia —

Institut de Pharmacologie Moléculaire et Cellulaire, Sophia-Antipolis, France

"Acid-sensing ion channels (ASICs): potential therapeutic targets for the treatment of pain"

16.00 — 16.15 COFFEE BREAK

16.15 — 17.15

Michel Wurm —

VP Medical affairs, Pharmaleads, Paris, France

"Enhancing endogenous opioid concentrations using Dual Enkephalinase Inhibitors (DENKI®): Therapeutic potential for acute and chronic severe pain and for opioid withdrawal disorders"

17.15 — 18.00 Round table

Medical needs raised by clinicians, new therapeutic approaches and the robustness of models, targets and research tools.

Program and registration at www.neurex.org

